

Young E Whang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3171839/publications.pdf>

Version: 2024-02-01

65
papers

3,981
citations

136950
32
h-index

118850
62
g-index

68
all docs

68
docs citations

68
times ranked

5252
citing authors

#	ARTICLE	IF	CITATIONS
1	Epstein-barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. <i>Cell</i> , 1987, 50, 203-213.	28.9	481
2	Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. <i>Nature</i> , 1996, 382, 272-274.	27.8	232
3	Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 8438-8443.	7.1	223
4	Activated Tyrosine Kinase Ack1 Promotes Prostate Tumorigenesis: Role of Ack1 in Polyubiquitination of Tumor Suppressor Wwox. <i>Cancer Research</i> , 2005, 65, 10514-10523.	0.9	186
5	Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1502-1507.	1.6	185
6	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	1.6	169
7	Zinc-induced PTEN Protein Degradation through the Proteasome Pathway in Human Airway Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 28258-28263.	3.4	139
8	Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. <i>Prostate</i> , 2006, 66, 1292-1301.	2.3	129
9	Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth. <i>Clinical Cancer Research</i> , 2005, 11, 1704-1712.	7.0	124
10	PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. <i>Oncogene</i> , 2002, 21, 319-327.	5.9	121
11	Acidities of carboxamides, hydroxamic acids, carbohydrazides, benzenesulfonamides, and benzenesulfonohydrazides in DMSO solution. <i>Journal of Organic Chemistry</i> , 1990, 55, 3330-3336.	3.2	118
12	PTEN Blocks Tumor Necrosis Factor-induced NF- κ B-dependent Transcription by Inhibiting the Transactivation Potential of the p65 Subunit. <i>Journal of Biological Chemistry</i> , 2002, 277, 11116-11125.	3.4	113
13	A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. <i>BJU International</i> , 2010, 106, 349-354.	2.5	95
14	Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer. <i>Cancer Research</i> , 2005, 65, 3404-3409.	0.9	88
15	A multidisciplinary approach to the management of urologic malignancies: Does it influence diagnostic and treatment decisions?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 378-382.	1.6	86
16	Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. <i>Cancers</i> , 2017, 9, 67.	3.7	83
17	A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 82-86.	1.6	74
18	Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3140-3148.	1.6	72

#	ARTICLE	IF	CITATIONS
19	A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer. <i>Cancer</i> , 2011, 117, 526-533.	4.1	70
20	ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. <i>Molecular Cell</i> , 2018, 72, 341-354.e6.	9.7	64
21	Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. <i>Molecular Cancer Therapeutics</i> , 2003, 2, 789-95.	4.1	58
22	The impact of altered annexin I protein levels on apoptosis and signal transduction pathways in prostate cancer cells. <i>Prostate</i> , 2006, 66, 1413-1424.	2.3	57
23	Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 582-589.	4.7	57
24	A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 669-676.	2.6	54
25	Signal transduction by wild-type and leukemogenic Abl proteins. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1997, 1333, F201-F216.	7.4	53
26	p38 and EGF receptor kinase-mediated activation of the phosphatidylinositol 3-kinase/Akt pathway is required for Zn2+-induced cyclooxygenase-2 expression. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2005, 289, L883-L889.	2.9	49
27	Human epidermal receptor-2 expression in prostate cancer. <i>Clinical Cancer Research</i> , 2003, 9, 1087-97.	7.0	47
28	Functional role for the c-Abl tyrosine kinase in meiosis. <i>Oncogene</i> , 1998, 16, 1773-1777.	5.9	45
29	The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. <i>Gynecologic Oncology</i> , 2006, 101, 305-310.	1.4	44
30	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 275-282.e1.	1.9	42
31	Regulation of Sensitivity to TRAIL by the PTEN Tumor Suppressor. <i>Vitamins and Hormones</i> , 2004, 67, 409-426.	1.7	37
32	Estrogen-receptor-dependent regulation of telomerase activity in human endometrial cancer cell lines. <i>Gynecologic Oncology</i> , 2006, 103, 417-424.	1.4	37
33	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	2.9	35
34	Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: A search for biomarkers of sensitivity to treatment. <i>Gynecologic Oncology</i> , 2010, 119, 579-585.	1.4	32
35	Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1369-1378.	2.4	30
36	Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest. <i>Gynecologic Oncology</i> , 2006, 100, 487-494.	1.4	29

#	ARTICLE	IF	CITATIONS
37	Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule. <i>Npj Precision Oncology</i> , 2017, 1, .	5.4	29
38	Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. <i>British Journal of Cancer</i> , 2018, 119, 801-807.	6.4	29
39	Phase I trial of docetaxel plus lutetium-177-labeled anti-“prostate-specific membrane antigen monoclonal antibody J591 (177Lu-591) for metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 848.e9-848.e16.	1.6	29
40	Identification of a Pseudogene That Can Masquerade as a Mutant Allele of the PTEN/MMAC1 Tumor Suppressor Gene. <i>Journal of the National Cancer Institute</i> , 1998, 90, 859-861.	6.3	28
41	Role of Phosphoinositide 3-Kinase in the Aggressive Tumor Growth of HT1080 Human Fibrosarcoma Cells. <i>Molecular and Cellular Biology</i> , 2001, 21, 5846-5856.	2.3	26
42	Arrays of high-aspect ratio microchannels for high-throughput isolation of circulating tumor cells (CTCs). <i>Microsystem Technologies</i> , 2014, 20, 1815-1825.	2.0	25
43	Renal cell carcinoma. <i>Current Opinion in Oncology</i> , 2003, 15, 213-216.	2.4	24
44	Cistrome analysis of YY1 uncovers a regulatory axis of YY1:BRD2/4-PFKP during tumorigenesis of advanced prostate cancer. <i>Nucleic Acids Research</i> , 2021, 49, 4971-4988.	14.5	22
45	Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 909-916.	2.3	20
46	Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2015, 33, 751-754.	2.6	18
47	Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. , 2019, 7, 4.		18
48	Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. <i>BJU International</i> , 2012, 110, E721-6.	2.5	17
49	Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 608-613.	1.6	15
50	Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer. <i>Anti-Cancer Drugs</i> , 2011, 22, 299-302.	1.4	15
51	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 386.e1-386.e6.	1.6	15
52	Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. <i>British Journal of Cancer</i> , 2019, 121, 237-248.	6.4	15
53	Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). <i>Clinical Genitourinary Cancer</i> , 2020, 18, 378-386.e1.	1.9	15
54	Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding. <i>PLoS ONE</i> , 2015, 10, e0126270.	2.5	12

#	ARTICLE	IF	CITATIONS
55	Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database”UNC GOLD. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 32.e1-32.e9.	1.6	8
56	Hypertriglyceridemia and Pancreatitis Associated With Estramustine Phosphate. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 342-343.	1.3	7
57	Interaction between androgen receptor and coregulator SLIRP is regulated by Ack1 tyrosine kinase and androgen. Scientific Reports, 2019, 9, 18637.	3.3	7
58	A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. PLoS ONE, 2021, 16, e0253021.	2.5	6
59	Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 725-732.	3.9	5
60	Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, , .	3.9	5
61	Genomic Profiling of Cancers of Unknown Primary Site. JAMA Oncology, 2015, 1, 541.	7.1	4
62	Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints. Investigational New Drugs, 2018, 36, 1143-1146.	2.6	4
63	Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer. Urology, 2021, 155, 192-198.	1.0	3
64	Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer. Annals of Translational Medicine, 2016, 4, S64-S64.	1.7	1
65	Intercellular Targets of Prostate Cancer. , 2007, , 475-486.		0